Cover Image
Market Research Report
Product code 
1084360

Alzheimer's Drugs Market Size and Share - Global Forecast, 2022 - 2028

Published: | Coherent Market Insights | 180 Pages | Delivery time: 2-3 business days

Price

Back to Top
Alzheimer's Drugs Market Size and Share - Global Forecast, 2022 - 2028
Published: May 10, 2022
Coherent Market Insights
Content info: 180 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.

Market Dynamics

Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2021, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2021, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to  prevent or delay symptoms of Alzheimer's disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2021, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.

Key features of the study:

This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global Alzheimer’s drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Alzheimer’s drugs market

Detailed Segmentation:

Global Alzheimer’s Drugs Market, By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

Global Alzheimer’s Drugs Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

Global Alzheimer’s Drugs Market, By Geography:

North America

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

U.S.

Canada

Latin America

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

GCC

Israel

Rest of Middle East

Africa

By Drugs:

Donepezil

Rivastigmine

Galantamine

Memantine

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

South Africa

Central Africa

North Africa

Company Profiles

Pfizer, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Developments

Key Strategies

Janssen Pharmaceuticals

Novartis International AG

Eisai Co. Ltd

Lundbeck A/S

Teva Pharmaceuticals Industries Ltd

Daichi Sankyo Company Limited

“*” marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1373

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drugs
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Key Highlights
  • Pipeline Analysis
  • Regulatory Guidelines
  • Epidemiology

4. Global Alzheimer's Drugs Market, By Drugs, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Donepezil
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Rivastigmine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Galantamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Memantine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Alzheimer's Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • e-Commerce
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Alzheimer's Drugs Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
    • Pfizer Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Janssen Pharmaceutical.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Teva Pharmaceuticals ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Eisai Co Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Lundbeck A/S.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
    • Daichi Sankyo Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Developments
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact